Core Viewpoint - The company, Xingfa Group, is experiencing steady growth in revenue and net profit due to the optimization of the glyphosate supply-demand structure and the continuous improvement in the utilization rate of new energy production capacity [1] Group 1: Glyphosate Market - Glyphosate raw material prices are expected to remain stable or increase, supported by a tight supply situation and downstream replenishment demand [1] - Glyphosate prices have been at low levels since 2024, reaching a phase low in March 2025 before starting a recovery trend [1] - The company anticipates that the overall supply side of the industry will remain tight in the fourth quarter, enhancing cost support due to the seasonal reduction in raw material supply [1] Group 2: Specialty Chemicals Segment - The specialty chemicals segment accounted for approximately 17% of the company's total revenue in the first three quarters, with a gross margin exceeding 25% [2] - The company is in the product ramp-up phase for several products, including 5,000 tons/year of phosphonates and 3,000 tons/year of ethanethiol, with additional production capacity expected to come online soon [2] - The sales volume of organic silicon ring bodies increased by about 30% year-on-year, with expectations for gradual price recovery in the coming years due to no new production capacity in the industry [2] Group 3: Research and Development - The company is accelerating its layout in solid-state electrolytes and liquid cooling silicone oil, with ongoing development of key process parameters for solid-state electrolytes [2][3] - The company has a production capacity of approximately 170,000 tons/year of yellow phosphorus and is building an additional 10,000 tons/year of high-end pentasulfide capacity [3] - The company is actively developing the market for liquid cooling silicone oil, with a total capacity of 56,000 tons/year and ongoing product performance optimization based on customer requirements [3]

Core Insights - Xingfa Group has achieved full production and sales of its iron phosphate products, with product performance ranking among the industry's top [1] - The utilization rate of lithium iron phosphate production capacity continues to improve, and the company has proactively developed fourth and fifth generation ultra-high pressure solid lithium iron phosphate products, making positive progress [1] - To further enhance product profitability and customer service capabilities, the company plans to add 50,000 tons/year of iron phosphate capacity at the beginning of next year and an additional 100,000 tons/year by mid-year [1]

Investment Rating - Investment Rating: Buy (Maintain) [1] Core Views - The company reported a significant increase in net profit quarter-on-quarter, driven by improved market conditions for glyphosate [5] - The company achieved a revenue of 23.781 billion yuan in the first three quarters of 2025, a year-on-year increase of 7.8%, with a net profit attributable to shareholders of 1.318 billion yuan, a year-on-year increase of 0.3% [4][5] - The third quarter saw revenue of 9.161 billion yuan, a year-on-year increase of 6.0% and a quarter-on-quarter increase of 23.9%, with a net profit of 0.592 billion yuan, a year-on-year increase of 16.2% and a quarter-on-quarter increase of 42.1% [5] Summary by Sections Financial Performance - The company’s revenue and net profit showed steady growth, with significant quarter-on-quarter improvement in Q3, primarily due to the optimized supply-demand dynamics of glyphosate and the profit contribution from phosphate fertilizer exports [5] - Glyphosate market prices have risen, with current average prices at 26,546 yuan/ton, reflecting increases of 14% and 17% compared to Q1 2025 [5] Industry Outlook - The phosphate industry remains robust, with the company enhancing its mining integration and exploration efforts, increasing phosphate resource reserves to 580 million tons [6] - The company is actively pursuing acquisitions to strengthen its integrated layout in the phosphate chemical industry [6] New Materials Business - The company has successfully turned around its new energy products to profitability and is expanding its special chemicals and silicone businesses, which are crucial for high-quality development [7] - New projects in the organic silicon sector are expected to become new profit growth points, with significant investments planned for industrial silicon production [8] Investment Recommendations - The company is projected to achieve net profits of 1.825 billion, 2.078 billion, and 2.366 billion yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 17, 15, and 13 times [9]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Insights - The company reported a significant improvement in Q3 performance, with revenue reaching 91.6 billion yuan, a year-on-year increase of 6.0% and a quarter-on-quarter increase of 23.9%. The net profit attributable to shareholders for Q3 was 5.9 billion yuan, up 16.2% year-on-year and 42.1% quarter-on-quarter [2][7]. - For the first three quarters of 2025, the company achieved a total revenue of 237.8 billion yuan, a year-on-year increase of 7.8%, and a net profit of 13.2 billion yuan, a slight increase of 0.3% year-on-year [2][7]. Summary by Sections Financial Performance - In Q3, the company achieved a net profit of 5.9 billion yuan, with a year-on-year growth of 16.2% and a quarter-on-quarter growth of 42.1%. The revenue for Q3 was 91.6 billion yuan, reflecting a year-on-year increase of 6.0% and a quarter-on-quarter increase of 23.9% [2][7]. - For the first three quarters of 2025, the company reported a total revenue of 237.8 billion yuan, which is a 7.8% increase compared to the same period last year. The net profit attributable to shareholders was 13.2 billion yuan, showing a modest increase of 0.3% year-on-year [2][7]. Market Outlook - The company is positioned to benefit from a potential recovery in the prices of glyphosate and organic silicon, driven by overseas demand and supply disruptions. The price of glyphosate has recently increased, contributing positively to the company's performance [10]. - The company has a robust production capacity of 230,000 tons per year for glyphosate and 600,000 tons per year for organic silicon, indicating significant operational leverage as market conditions improve [10]. Strategic Developments - The company is expanding its specialty chemicals segment, with new projects in solid-state battery materials expected to ramp up production. The company is also acquiring a 50% stake in Qiaogou Mining, which will enhance its resource capabilities [10]. - The company has a comprehensive industrial chain and strong R&D capabilities, which are expected to support its recovery as market conditions improve and new projects come online [10].

Core Points - The company announced a change in the designated sponsor representative for its 2022 convertible bond issuance due to personal work adjustments of the previous representative [2] - The new sponsor representative, Mr. Li Dashan, will take over the responsibilities from Ms. Wu Yi, ensuring the continuity of supervision over the remaining raised funds [2] - The change in representatives will not affect the ongoing supervision of the company's convertible bond issuance [2] Summary by Sections Company Announcement - Hubei Xingfa Chemical Group Co., Ltd. has confirmed the change of its sponsor representative for the 2022 convertible bond issuance, with the new representative being Mr. Li Dashan [1][2] - The company assures that the announcement contains no false records or misleading statements and takes responsibility for its accuracy [1] Sponsor Representative Details - Mr. Li Dashan holds a Master's degree in Business Administration and has qualifications as a Certified Public Accountant and a Certified Tax Agent [4] - He has a solid background in financial auditing and tax consulting, with experience in various significant projects, ensuring compliance with relevant regulations [4] - The previous representative, Ms. Wu Yi, will no longer fulfill her duties, and the supervision will continue until the raised funds are fully utilized [2][4]

Group 1: Company Performance - The company achieved a revenue of 1.40 billion yuan in the first half of 2025, representing a year-on-year growth of 62.36%[1] - The net profit for 2025 is projected to be 640 million yuan, with a growth rate of 127% compared to 2024[1] - The EPS for 2025 is expected to be 0.2, up from 0.1 in 2024[1] Group 2: Market Trends - The AI-enabled revenue has become a core driver of performance, with significant contributions from products like AI-MDT reports and lung cancer screening[1] - The company is expanding its product matrix with new AI-driven health management products, indicating a strong focus on innovation[1] Group 3: Strategic Initiatives - The company is implementing an "All in AI" strategy, which has shown significant operational improvements and efficiency gains[1] - Collaborations with major tech firms like Alibaba for developing innovative screening products highlight the company's commitment to leveraging AI technology[1] Group 4: Risks and Challenges - Potential risks include ongoing industry policy impacts, declining customer prices, and the possibility of AI application not meeting expectations[1] - The company faces competition in the AI healthcare space, which may affect its market position and growth trajectory[1]

Core Viewpoint - Xingfa Group announced a change in the representative for ongoing supervision of its 2022 convertible bond issuance, ensuring that the supervisory responsibilities will continue without disruption [2]. Group 1 - On October 31, Xingfa Group received a letter from Guolian Minsheng Securities Co., Ltd. regarding the replacement of the ongoing supervisory representative [2]. - The previous representative, Ms. Wu Yi, is stepping down due to personal work adjustments, and Mr. Li Dashan will take over the role [2]. - The change in representatives will not affect the ongoing supervision of the company's 2022 convertible bond issuance [2].

湖北兴发化工集团股份有限公司 关于变更保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券简称：兴发集团 证券代码：600141 公告编号：临2025-056 转债简称：兴发转债 转债代码：110089 湖北兴发化工集团股份有限公司 董事会 2025 年11 月1 日 附件： 保荐代表人李大山先生简历 李大山先生，保荐代表人，工商管理硕士，注册会计师资格、注册税务师 资格，现任国联民生证券承销保荐有限公司业务董事，曾在大信会计师事务所 担任审计经理从事财务审计及税务咨询工作，曾参与龙江交通 2013 年非公开 发行、华测检测 2014 年资产收购、华测检测2015 年非公开发行项目，负责森 霸股份首发上市项目，目前担任传美讯向不特定合格投资者公开发行股票并在 北京证券交易所上市项目(在审)的保荐代表人，在保荐业务执业过程中严格遵 守《保荐业务管理办法》等相关规定，执业记录良好，无监管机构处罚记录。 湖北兴发化工集团股份有限公司（以下简称"公司"）2022 年公开发行可 转换公司债券的保荐机构为国联民生证 ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company has reported a stable performance in Q3 2025, benefiting from the rise in glyphosate prices and significant export premiums for phosphate fertilizers, leading to a quarter-on-quarter growth [1][6] - The phosphate rock prices remain high, and the company anticipates substantial incremental growth due to its acquisition of a 50% stake in Qiaogou Mining, which has a resource reserve of 185 million tons [6] - The company’s fertilizer sales volume increased significantly, and it is expected to benefit from the export premium in the phosphate fertilizer sector [6] - The organic silicon segment is under short-term pressure but is expected to improve in the long term due to a lack of new capacity in the industry [6] Financial Data and Profit Forecast - Total revenue for 2024 is projected at 28,396 million, with a year-on-year growth rate of 0.4% [2] - The net profit attributable to the parent company for 2025 is estimated at 1,805 million, reflecting a 12.7% year-on-year increase [2] - The earnings per share (EPS) for 2025 is forecasted to be 1.64 yuan, with a price-to-earnings (PE) ratio of 17 [2] - The gross margin is expected to be 19.3% in 2025, with a return on equity (ROE) of 7.9% [2] Market Data - As of October 29, 2025, the closing price of the stock is 28.41 yuan, with a market capitalization of 31,344 million [3] - The stock has a dividend yield of 3.52% based on the most recent dividend announcement [3] - The stock's price-to-book ratio is 1.4, indicating a moderate valuation relative to its book value [3] Performance Analysis - In Q3 2025, the company achieved a revenue of 91.61 billion, marking a year-on-year increase of 6% and a quarter-on-quarter increase of 24% [6] - The net profit for Q3 2025 was 5.92 billion, reflecting a year-on-year growth of 16% and a quarter-on-quarter growth of 42% [6] - The company’s gross margin for Q3 2025 was 17.32%, with a net margin of 7.41% [6]

湖北兴发化工集团股份有限公司 2025 年第二次临时股东会 会 议 材 料 湖北兴发化工集团股份有限公司董事会 二O 二五年十一月十二日 会议议程 会议时间：2025 年 11 月 12 日（星期三）14:30 会议地点：湖北省宜昌市伍家岗区沿江大道 188-9 号兴发大厦会议室 会议议程： 一、主持人宣布本次股东会开始，宣布出席会议股东、董事、 监事、高管以及见证律师情况 - 1 - 为维护股东的合法权益，确保兴发集团2025年第二次临时股东 会的正常秩序和议事效率，根据《公司法》《公司章程》和《股东 会议事规则》的有关规定，现就会议须知通知如下，望参加本次会 议的全体人员遵守。 一、本次会议期间，全体参会人员应以维护股东的合法权益， 确保会议的正常秩序和议事效率为原则，自觉履行法定义务。 二、为保证本次会议的严肃性和正常秩序，除出席会议的股东 及股东代理人、董事、监事、董事会秘书、高级管理人员、公司聘 任律师及公司董事会邀请的人员以外，公司有权依法拒绝其他人员 入场，对于干扰会议秩序，寻衅滋事和侵犯其他股东合法权益的行 为，公司有权予以制止并及时报告有关部门查处。 三、公司董事会秘书负责本次会议的会务事宜 ...